Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-08-31 19:06:27 ET · period of report 2026-08-27 · accession 0001193125-26-377207 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-31 19:06 | 2026-08-27 | ARTV | Banerjee Subhashis | Chief Medical Off | M - OptEx | $1.92 | +5,306 | 150.3K | +4% | +$10.2K |
| DT | 2026-08-31 19:06 | 2026-08-27 | ARTV | Banerjee Subhashis | Chief Medical Off | S - Sale+OE | $12.01 | -8,222 | 142.0K | -5% | -$98.7K |
| DT | 2026-08-31 19:06 | 2026-08-27 | ARTV | Banerjee Subhashis | Chief Medical Off | M - OptEx | $0.00 | -5,306 | 74.3K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-27 | M | A | 5,306 | $1.92 | 150,269 | D | — | — | (F1) The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. |
| 2 | Common | Common Stock | 2026-08-27 | S | D | 8,222 | $12.01 | 142,047 | D | — | — | (F1) The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. (F2) The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2026-08-27 | M | D | 5,306 | $0.00 | 74,265 | D | $1.92 · — to 2035-04-07 | 5,306 Common Stock | (F1) The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. (F3) 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months. |